Treatment of Chronic Hepatitis B in HBsAg-Positive Patients with Viremia at High Risk of Horizontal HBV Transmission
This protocol applies to a specific and clinically important subgroup: HBsAg-positive individuals who have detectable viremia yet do not meet conventional disease-specific thresholds for antiviral treatment, but who are in a situation that poses a significant risk of transmitting HBV horizontally to others.
Clinical Scenario
HBsAg-positive with viremia not meeting disease-specific treatment indications, in a high-risk scenario for horizontal transmission of HBV to HBsAg-negative persons. Standard treatment eligibility criteria alone do not resolve the clinical question when ongoing transmission risk is present.
Treatment Goals
- Suppression of HBV DNA to less than the lower limit of quantification
- For healthcare workers performing SHEA Category III procedures: HBV DNA below 1000 IU/mL
Approach — Partial Overview
Oral antiviral therapy is approached through a shared decision-making process, with the duration of therapy tied to the persistence of the high-risk transmission scenario.
References
Population: HBsAg-positive persons in high-risk settings to transmit to HBsAg-negative persons
For persons who are HBsAg-positive with viremia not meeting disease-specific treatment indications and who are in high-risk scenarios for transmission to others, AASLD suggests a shared decision-making approach regarding antiviral treatment.
Once initiated for the prevention of HBV transmission, antiviral therapy should be continued until the high risk of transmission is no longer present
Though there are no definitive studies on the lowest level of viral load transmissibility, the goal of HBV treatment is HBV DNA suppression to less than the lower limit of quantification
For health care providers performing Category III procedures, the Society for Healthcare Epidemiology of America (SHEA) guidelines suggest maintaining HBV DNA < 1000 IU/mL
View source ↗